Last reviewed · How we verify

NCT01516528: ACCESS

Assessment of Comorbidities in Chronic Obstructive Pulmonary Disease (COPD) in European Symptomatic Subjects From Primary Care

Completed Last updated 20 September 2017
What this trial tests

trial testing Spirometry in Pulmonary Disease, Chronic Obstructive in 3,500 participants. Completed in 12 June 2015.

Timeline
17 November 2011
Primary endpoint
1 May 2015
12 June 2015

Quick facts

Lead sponsorGlaxoSmithKline
StatusCompleted
Study typeOBSERVATIONAL
Enrollment3,500
Start date17 November 2011
Primary completion1 May 2015
Estimated completion12 June 2015
Sites233 locations across France, Netherlands, Belgium, Germany, Poland, Spain

Drugs / interventions tested

Conditions studied

Sponsor

GlaxoSmithKline — full company profile →

Who can join

40 and older, any sex, with Pulmonary Disease, Chronic Obstructive. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, observational, non-drug interventional, non-randomized study to compare the rate of moderate-severe COPD exacerbations in patients of all Chronic Obstructive Pulmonary Disease (COPD) severities with and without cardiovascular diseases. A total study population of 3330 subjects will be recruited by general practitioners (GPs) and assessed over a 27 month time frame.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Spirometry

Trials testing the same drug.

Other recruiting trials for Pulmonary Disease, Chronic Obstructive

Currently open trials in the same condition.

Other GlaxoSmithKline trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01516528.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing